Loading...
Loading...
Valeant Pharmaceuticals International
VRX reported a profit in the second quarter and lifted its full-year profit forecast.
Valeant posted a quarterly profit of $10.9 million, or $0.03 per share, versus a year-ago loss of $21.6 million, or $0.07 per share.
It lifted its full-year adjusted profit forecast to $6.00 to $6.20 per share, versus its earlier outlook of $5.55 to $5.85 per share.
Valeant shares closed at $95.72 yesterday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in